AMRN---from another site, someone wrote: "the PTO said the application's claim weren't patentable because they amount to "double" patenting of claims cited in another patent aplication. The other patent application is pending and covers the composition of the drug".
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.